European CHMP recommends approval of use of Spikevax (previously COVID-19 Vaccine Moderna) in younger patients, European Medicines Agency

The CHMP has adopted an extension to the existing indication to include use of Spikevax bivalent Original/Omicron BA.4-5 as a booster in children aged 6 to 11 years [currently licensed only for use in individuals aged 12 years and older].
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news